Drugs / BIIB015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00674947 | Jun 2008 → Jun 2011 | cancer | Biogen | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2008-02-01 | AbbVie | Regulatory ImmunoGen, Inc. Earns Milestone with IND Filing for BIIB015 abbvie.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-02-01 | AbbVie | ImmunoGen, Inc. Earns Milestone with IND Filing for BIIB015 abbvie.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00674947 ↗ |
| Modality | Monoclonal antibody | “Monoclonal Antibody” NCT00674947 ↗ |
| Route | Intravenous | “IV infusion once every 3 weeks until disease progression or unacceptable toxicity” NCT00674947 ↗ |
| Target | CRIPTO | “Teratocarcinoma-derived growth factor 1 binding agent” CHEMBL2109575 ↗ |